UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis

Rheumatic & musculoskeletal diseases open, 2020-02, Vol.6 (1), p.e001117

2020

Volltextzugriff (PDF)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

BMJ open, 2020-08, Vol.10 (8), p.e032552-e032552

2020

Volltextzugriff (PDF)

Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine

BMC health services research, 2008-09, Vol.8 (1), p.194-194, Article 194

2008

Volltextzugriff (PDF)

Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review

International journal of technology assessment in health care, 2008-10, Vol.24 (4), p.465-472

2008

Volltextzugriff (PDF)

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

BMC neurology, 2012-02, Vol.12 (1), p.2-2, Article 2

2012

Volltextzugriff (PDF)

COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US

Gastroenterology (New York, N.Y. 1943), 2024-02, Vol.166 (3), p.S61-S62

2024

Volltextzugriff (PDF)

COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US

Inflammatory bowel diseases, 2024-01, Vol.30 (Supplement_1), p.S44-S45

2024

Volltextzugriff (PDF)

Su1801 TREATMENT SATISFACTION AMONG ULCERATIVE COLITIS PATIENTS WITH AND WITHOUT BOWEL URGENCY – A GLOBAL REAL-WORLD ANALYSIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-688-S-689

2023

Volltextzugriff (PDF)

Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study

Current medical research and opinion, 2023-12, Vol.39 (12), p.1695-1705

2023

Volltextzugriff (PDF)

Su1535: CLINICAL PROFILE AND REAL WORLD OUTCOMES OF ULCERATIVE COLITIS PATIENTS RECEIVING STANDARD AND ESCALATED DOSES OF TARGETED THERAPIES - FINDINGS FROM A GLOBAL STUDY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-618-S-619

2022

Volltextzugriff (PDF)

S968 Healthcare Resource Utilization and Treatment Usage Among Flaring and Non-Flaring Patients with Ulcerative Colitis – A Real-World Global Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S729-S730

2023

Volltextzugriff (PDF)

S904 Burden of Bowel Urgency Across Specific Treatment Groups Among Crohn’s Disease Patients: Real World Global Study Analyses

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e656-e656

2022

Volltextzugriff (PDF)

Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe

Current medical research and opinion, 2023-09, Vol.39 (9), p.1205-1214

2023

Volltextzugriff (PDF)

Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy

Advances in therapy, 2024-06, Vol.41 (6), p.2282-2298

2024

Volltextzugriff (PDF)

Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe

Current medical research and opinion, 2023-08, p.1

2023

Volltextzugriff (PDF)

Burden of Bowel Urgency in Patients with Ulcerative Colitis and Crohn’s Disease: A Real-World Global Study

Crohn's & colitis 360, 2024-08

2024

Volltextzugriff (PDF)

EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis

Journal of medical economics, 2017-01, Vol.20 (1), p.19-27

2017

Volltextzugriff (PDF)

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK

Journal of medical economics, 2018-08, Vol.21 (8), p.810-820

2018

Volltextzugriff (PDF)

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

Journal of medical economics, 2017-12, Vol.20 (12), p.1224-1230

2017

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

PharmacoEconomics - open, 2020-12, Vol.4 (4), p.635-648

2020

Volltextzugriff (PDF)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

ClinicoEconomics and outcomes research, 2018-01, Vol.10, p.747-759

2018

Volltextzugriff (PDF)

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Health policy (Amsterdam), 2009-02, Vol.89 (2), p.184-192

2009

Volltextzugriff (PDF)

Trophic transfer, bioaccumulation and transcriptomic effects of permethrin in inland silversides, Menidia beryllina, under future climate scenarios

Environmental pollution (1987), 2021-04, Vol.275, p.116545, Article 116545

2021

Volltextzugriff (PDF)

Exposure to permethrin or chlorpyrifos causes differential dose- and time-dependent behavioral effects at early larval stages of an endangered teleost species

Endangered species research, 2021-01, Vol.44 (1), p.89-103

2021

Volltextzugriff (PDF)

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Circulation (New York, N.Y.), 2024-01, Vol.149 (5), p.343

2024

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(32)
Buchkapitel
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine

Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US

COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US

Su1801 TREATMENT SATISFACTION AMONG ULCERATIVE COLITIS PATIENTS WITH AND WITHOUT BOWEL URGENCY – A GLOBAL REAL-WORLD ANALYSIS

Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study

Su1535: CLINICAL PROFILE AND REAL WORLD OUTCOMES OF ULCERATIVE COLITIS PATIENTS RECEIVING STANDARD AND ESCALATED DOSES OF TARGETED THERAPIES - FINDINGS FROM A GLOBAL STUDY

S968 Healthcare Resource Utilization and Treatment Usage Among Flaring and Non-Flaring Patients with Ulcerative Colitis – A Real-World Global Study

S904 Burden of Bowel Urgency Across Specific Treatment Groups Among Crohn’s Disease Patients: Real World Global Study Analyses

Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe

Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy

Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe

Burden of Bowel Urgency in Patients with Ulcerative Colitis and Crohn’s Disease: A Real-World Global Study

EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK

Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Trophic transfer, bioaccumulation and transcriptomic effects of permethrin in inland silversides, Menidia beryllina, under future climate scenarios

Exposure to permethrin or chlorpyrifos causes differential dose- and time-dependent behavioral effects at early larval stages of an endangered teleost species

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Suchergebnisse filtern